Sustained and localized in vitro release of BMP-2/7, RANKL, and tetracycline from FlexBone, an elastomeric osteoconductive bone substitute.

Sustained and localized in vitro release of BMP-2/7, RANKL, and tetracycline from FlexBone, an elastomeric osteoconductive bone substitute.
复制标题

DOI:
10.1002/jor.20890
复制
发表时间:
2009-10
影响因子:
2.8
通讯作者:
Song, Jie
Song, Jie
中科院分区:
医学3区
文献类型:
--
作者:
Xu, Jianwen;Li, Xinning;Lian, Jane B.;Ayers, David C.;Song, Jie

文献摘要

参考文献

被引文献

相似文献

This study tests the hypothesis that synthetic composites containing a high percentage of osteoconductive biominerals well-integrated with a hydrophilic polymer matrix can be engineered to provide both the structural and biochemical framework of a viable synthetic bone substitute. FlexBone, an elastic hydrogel-mineral composite exhibiting excellent structural integration was prepared by crosslinking pHEMA hydrogel in the presence of 25wt% nanocrystalline hydroxyapatite and 25wt% tricalcium phosphate. Biologically active factors tetracycline, BMP-2/7 and RANKL that stimulate bone formation and remodeling were encapsulated into FlexBone during polymerization or via post-polymerization adsorption. SEM and DMA analyses showed that the encapsulation of tetracycline (5.0wt%) did not compromise the structural integrity and compressive behavior of FlexBone, which could withstand repetitive megapascal-compressive loadings and be securely press-fitted into critical femoral defects. Dose-dependent, sustained in vitro release of tetracycline from FlexBone was characterized by spectroscopy and bacterial inhibition. A single dose of 40-ng-BMP-2/7 or 10-ng-RANKL pre-encapsulated with 50-mg-FlexBone, released over 1 week, was able to locally induce osteogenic differentiation of myoblast C2C12 cells and osteoclastogenesis of macrophage RAW264.7 cells, respectively. With a bone-like structural composition, useful surgical handling characteristics and tunable biochemical microenvironment, FlexBone provides an exciting opportunity for the treatment of hard-to-heal skeletal defects with minimal systemic side effects.
DOI: 10.1002/jbm.a.32110
发表时间: 2009-06-15
影响因子: 4.9
作者:
Song, Jie;Xu, Jianwen;Filion, Tera;Saiz, Eduardo;Tomsia, Antoni P.;Lian, Jane B.;Stein, Gary S.;Ayers, David C.;Bertozzi, Carolyn R.
通讯作者: Bertozzi, Carolyn R.
DOI: 10.1089/ten.tea.2007.0229
发表时间: 2008-08-01
影响因子: 4.1
作者:
Abarrategi, Ander;Moreno-Vicente, Carolina;Lopez-Lacomba, Jose Luis
通讯作者: Lopez-Lacomba, Jose Luis
DOI: 10.3109/08977199609003229
发表时间: 1996-01-01
期刊: GROWTH FACTORS
影响因子: 1.8
作者:
Israel, DI;Nove, J;Wozney, JM
通讯作者: Wozney, JM
DOI: 10.1007/s11420-005-0111-5
发表时间: 2005-09-01
期刊: HSS journal : the musculoskeletal journal of Hospital for Special Surgery
影响因子: --
作者:
Bostrom, Mathias P G;Seigerman, Daniel A
通讯作者: Seigerman, Daniel A
DOI: 10.1016/j.biomaterials.2008.03.035
发表时间: 2008-08-01
期刊: BIOMATERIALS
影响因子: 14
作者:
Le Nihouannen, Damien;Hacking, S. Adam;Barralet, Jake E.
通讯作者: Barralet, Jake E.